Today, the Exec. Vice Chairman of Hemispherx Biopharma Inc (HEB), Thomas Equels, bought shares of HEB for $118.5K.
Following this transaction Thomas Equels’ holding in the company was increased by 2.16% to a total of $5.62 million.
See today’s analyst top recommended stocks >>
Currently, Hemispherx Biopharma Inc has an average volume of 213.3K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen.
